Results 161 to 170 of about 4,729,806 (295)
Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra +6 more
wiley +1 more source
Product design improvement method driven by online product reviews. [PDF]
Cheng FM, Wang J, Chen C, Hu GR, Cao ZJ.
europepmc +1 more source
An evaluation method for product design solutions for healthy aging companionship. [PDF]
Hu S +5 more
europepmc +1 more source
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson +9 more
wiley +1 more source
Research on product design priority allocation based on user characteristics classification. [PDF]
Wang Y, He J, Yang W, Kim KS.
europepmc +1 more source
How Industry 4.0 and Sensors Can Leverage Product Design: Opportunities and Challenges. [PDF]
Rosário AT, Dias JC.
europepmc +1 more source
Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...
Weida Wang +12 more
wiley +1 more source
Assessment of a Bioengineering and Nursing Student Partnership for Medical Product Design. [PDF]
Clark RM, Dukes AA, Sowko L, Gartner M.
europepmc +1 more source
Promoting active aging through assistive product design innovation: a preference-based integrated design framework. [PDF]
Zhang B, Ma M, Wang Z.
europepmc +1 more source
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla +9 more
wiley +1 more source

